Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

National Cheng-Kung Uni. Hosp., Tainan City

St Vincent's Hospital Sydney, Darlinghurst

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Cancer Center, Harrison

Memorial Sloan Kettering Cancer Center, Commack

The John Hopkins Hospital, Baltimore

Hospital Universitario 12 de Octubre, Madrid

Mayo Clinic in Florida, Jacksonville

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux

Sarah Cannon Cancer Center, Nashville

China Medical University Hospital, Taichung

Indiana University School of Medicine, Indianapolis

Mayo Clinic, Rochester

University of Chicago Pritzker School of Medicine, Chicago

University of Texas MD Anderson Cancer Center, Houston

South Texas Accelerated Research Therapeutics, LLC, San Antonio

Mayo Clinic of Scottsdale, Phoenix

The University of Arizona Cancer Center, Tucson

USC Norris Cancer Hospital, Los Angeles

Gustave Roussy, Villejuif

National University Hospital, Singapore

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Memorial Sloan Kettering Cancer Center, Middletown

Prince of Wales Hospital, Hong Kong

National Cancer Center Hospital East, Kashiwa

Kanagawa Cancer Center, Yokohama

Osaka University Hospital, Suita-shi

Shizuoka Cancer Center, Nakatogari

National Cancer Center Hospital, Chuo-ku

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Hospital Universitario Vall d'Hebron, Barcelona